Literature DB >> 10204806

Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites.

A P Manning1, A M Mes-Masson, R J Seymour, M Tetrault, D M Provencher, P N Tonin.   

Abstract

Abnormal FHIT gene expression has been reported in a variety of epithelial tumors shown to harbor deletions of chromosome 3p14, the chromosomal assignment of this gene. Recently, we described loss of heterozygosity of 3p in a subset of epithelial ovarian cancers. To investigate a potential role of the FHIT gene in ovarian cancer, we examined primary cell cultures derived from normal ovarian surface epithelium, ovarian tumors, and the cellular fraction of malignant ascites to determine the expression of FHIT by using reverse transcription-polymerase chain reaction. Included in this analysis were four spontaneously immortalized cell lines: three derived from malignant epithelial ovarian tumors (TOV21G, TOV112D, and TOV81D) and one from malignant ovarian ascites (OV90). OV90 was previously shown to harbor a deletion of the whole p arm of chromosome 3. The FHIT transcript was not detectable in two of 11 primary cultures derived from normal ovarian surface epithelium or in a primary culture derived from malignant ovarian ascites, whereas the remaining samples (34 malignant, eight borderline, and three benign specimens), exhibited identical expression patterns. In each case, this pattern was consistent with the co-expression of a normal FHIT transcript and a smaller transcript. DNA sequencing revealed that the abnormal-sized message lacked exons 4-7 (inclusive), which were deleted at their exact intron-exon splice sites. The aberrant-sized transcript was detectable by Northern blot analysis. There was no concordance between FHIT expression and loss of heterozygosity at the FHIT locus. Northern blot analysis also revealed that FHIT was differentially expressed, and the spontaneously immortalized cell lines TOV21G and TOV112D showed the highest level of expression. Because the same reverse transcription-polymerase chain reaction expression pattern was observed in both normal and tumor-derived primary cell cultures, these results argue against a significant role for FHIT in epithelial ovarian tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204806     DOI: 10.1002/(sici)1098-2744(199903)24:3<218::aid-mc8>3.0.co;2-a

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  6 in total

1.  VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Authors:  Karen Gambaro; Michael C J Quinn; Paulina M Wojnarowicz; Suzanna L Arcand; Manon de Ladurantaye; Véronique Barrès; Jean-Sébastien Ripeau; Ann M Killary; Elaine C Davis; Josée Lavoie; Diane M Provencher; Anne-Marie Mes-Masson; Mario Chevrette; Patricia N Tonin
Journal:  Mol Oncol       Date:  2013-01-16       Impact factor: 6.603

2.  Covering your bases: inheritance of DNA methylation in plant genomes.

Authors:  Chad E Niederhuth; Robert J Schmitz
Journal:  Mol Plant       Date:  2013-11-22       Impact factor: 13.164

3.  The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.

Authors:  Sandra Sernbo; Elin Gustavsson; Donal J Brennan; William M Gallagher; Elton Rexhepaj; Frida Rydnert; Karin Jirström; Carl Ak Borrebaeck; Sara Ek
Journal:  BMC Cancer       Date:  2011-09-24       Impact factor: 4.430

4.  Functional role of the Tau protein in epithelial ovarian cancer cells.

Authors:  Aisa Yamauchi; Asami Kobayashi; Hiroe Oikiri; Yoshihito Yokoyama
Journal:  Reprod Med Biol       Date:  2017-03-20

5.  Multicellular detachment generates metastatic spheroids during intra-abdominal dissemination in epithelial ovarian cancer.

Authors:  Sara Al Habyan; Christina Kalos; Joseph Szymborski; Luke McCaffrey
Journal:  Oncogene       Date:  2018-05-23       Impact factor: 9.867

6.  Human ovarian surface epithelial cells immortalized with hTERT maintain functional pRb and p53 expression.

Authors:  N F Li; S Broad; Y J Lu; J S Yang; R Watson; T Hagemann; G Wilbanks; I Jacobs; F Balkwill; D Dafou; S A Gayther
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.